Privacy Policy

The purpose of this privacy policy is to inform you about how we use your personal data while you use the following website or mobile application:


We hereby, inform you that we, Mylan (hereinafter “Mylan” or “We”), collect and process your personal data that you voluntarily provide to us through our website/application


Mylan is likely to collect your personal data when

  • E.g. You complete the data collection form “Contact Us” in “Contact Mylan” section
  • E.g. You apply for a job in the “Mylan Career” section by using the following email address intended for recruitment purposes: recruitment@mylan.com., etc.] or by clicking on a link that redirects to a form to be completed on external websites managed by Mylan’s service providers (e.g. Taleo)
  • E.g. You use the following email addresses provided by Mylan for general or specific enquiries (e.g. request personal data, etc.)
  • E.g. You communicate with Mylan customer relations team.
  • E.g. You respond to surveys
  • E.g. You navigate in the websites. Indeed, the websites collect and store personal data that is generated automatically as you use it, including your preferences and anonymous usage statistics. When you visit the websites, we and our third-party service providers receive and record personal data on our server logs from your browser, including your IP address, and from cookies and similar technology (see specific section below).
  • E.g. You post comments or pictures on our social media pages (e.g. Facebook, Twitter, LinkedIn, Youtube, etc.)
  • Etc.


Mylan is likely to collect your personal data because

  • You have given consent to the processing of his or her personal data for one or more specific purposes or
  • The processing of your personal data is necessary for the performance of a contract to which you are party; or
  • Processing is necessary for compliance with a legal obligation to which Mylan is subject; or
  • Processing is necessary for the purposes of our legitimate interests, in particular


We collect and process the following personal data about you

  • E.g. Identification Data such as your first and last name, contact personal data such as email, any photographs, as provided by you etc.
  • E.g. Financial Personal data such as price of an application, invoice, bank account personal data, credit card personal data etc.
  • E.g. Family related personal data such personal data on family ties (children-parent) as may be required by certain applications.
  • E.g. Electronic identification data available on your computer (such as “cookies” or “IP addresses”)
  • E.g. Health data such as diseases, medical treatment followed, Mylan products consumed, etc) as provided by you by any relevant Mylan application you may use.
  • Etc.


In general, personal data you provide to us is used to

  • E.g. to provide and improve our services;
  • E.g. to communicate with you;
  • E.g. to respond to your request for information;
  • E.g. to inform you about our new products and services as well as about job opportunities within Mylan;
  • Etc.


Your personal data will be retained by Mylan until such time that the data is no longer necessary in relation to the purposes for which it is collected or otherwise processed.

Thus, Mylan applies the following data retention periods

  • E.g. Data related to the performance of a service (e.g. use of our applications) or a request of you prior to entering into a service contract with Mylan, is kept for the whole duration of the contract. After the end of the contract, this Data is archived for litigation purposes during the statutory limitation period.
  • E.g. Data related to marketing (including newsletters and data related to generic and specific inquiries of yours) is kept for XX years from the last communication Mylan had with you. At the end of this period, Mylan will contact you to know whether you wish to continue receiving communication. In case of a negative answer, or no response from you is received, this Data is archived for litigation purposes during the statutory limitation period.
  • E.g. Data related to the recruitment process is kept for XX years from the last communication Mylan had with you. At the end of this period, Mylan will contact you to know whether you wish to continue receiving communication. In case of a negative answer, or no response from you is received, this Data is archived for litigation purposes during the statutory limitation period.
  • Mylan applies the following data retention periods applicable to cookies and/or similar technologies used by Mylan


As you visit the website, Mylan is also likely to collect directly through cookies, server logs or or similar technology, personal data from your browser (including your IP address and your preferences), and anonymous usage statistics.

Therefore, we may use the personal data we obtain from your use of our cookies for the following purposes

  • e.g. to keep track of your input when filling online forms, shopping carts etc.
  • e.g. to identify you once you have logged in
  • e.g. to detect authentication abuses
  • e.g. to store technical data to play back video or audio content
  • e.g. for load-balancing purposes
  • e.g. to remember your custom preferences
  • e.g. for third party social plug-in content sharing cookies
  • e.g. for social plug-in tracking cookies
  • e.g. to conduct analytics and market research
  • e.g. for online behavioral target advertising
  • e.g. to allow third parties to track you for purposes of behavioral advertising, analytics or market research,

As a reminder, you have the right to object to the processing of your personal data through cookies. For that purpose, you may disable the installation of cookies by configuring your browser.

Any recent web browsers allow you to change the settings related to cookies. These settings are usually available in the section “Tools”, “options”, “help” or “preferences” in your browser.

Certain actions that you take to manage settings related to cookies will likely change your internet browsing experience, as well as your access conditions to some services requiring the use of cookies. We decline all liabilities for the consequences related to impaired operation of our services due to user refusal or deletion of cookie installation that is necessary for operation.


Mylan share your personal data with the following categories of recipients:

  • E.g. Mylan shares your Personal Data with any relevant Mylan subsidiaries and affiliates, on a need-to-know basis (e.g. share of recruitment data between the recruiting and the mother company etc.)
  • Mylan may also share your personal data with third parties under the following conditions:
    • E.g. You gave your prior consent to share personal data (for instance, to send you, on the sites and third parties sites, advertising adapted to your preferences);
    • E.g. Mylan needs to share such personal data with its service providers acting on our behalf, namely, our technical service providers such as maintenance and hosting providers or dub-processors which supply a service that you have requested (for example, when you apply for a job on the “Mylan Career” section);
    • E.g. Mylan receives a request from a judicial authority or any other legally authorized administrative authority asking that such personal data be disclosed in compliance with the laws in force.
    • Etc.


To offer its services, Mylan may need to transfer your personal data to countries other than the country in which the data was originally collected.

Those countries may not have the same data protection laws as the country in which you initially provided that personal data.

Regarding personal data transfers from the Mylan business located in your country, to Mylan N.V. offices located in the U.S.: Mylan N.V. has certified to the EU-U.S. Privacy Shield Framework as set forth by the Department of Commerce and the European Commission regarding the collection, storage, use, transfer, and other processing of personal data transferred from the EEA to the U.S. For more information about the Privacy Shield, or to see our certification, please see https://www.privacyshield.gov/list

Please also note that we may transfer your personal data to [COUNTRY] which has been recognized as a “safe country” in accordance with an adequacy decision of the EU commission.

Regarding personal data transfers from the Mylan business located in your country, to any other Mylan entity or third party provider located in a different country: Mylan puts in place adequate safeguards as defined by the European Commission with respect to the protection of the privacy and fundamental rights and freedoms of individuals, and those individual’s ability to exercise those corresponding rights.


You have the right to request from Mylan:

  • Access to, and rectification or erasure of, personal data
  • Restriction of processing of your personal data, or to object to such processing
  • Data portability (i.e., to request your personal data, in a structured, commonly used and machine-readable format).

When the processing is based on your consent, you have the right to withdraw consent at any time. You also have the right to lodge a complaint with the following supervisory authority:

To exercise your rights, you can contact us as indicated in the contact personal data section 14, below.


Mylan will use its best efforts to protect your personal data against damage, loss, disclosure, misappropriation, intrusion, alteration, or destruction. To help protect the privacy of data, we maintain physical, technical and administrative safeguards. We restrict access to your personal data to those who need to know that information to provide benefits or services to you. In addition, we train our employees about privacy.


Mylan does not knowingly collect, maintain or use personal data from children under 16 years old, and no part of the website/application is directed to children under the age of 16.

If you learn that personal data on children under the age of 16 has been collected by a Mylan website/application without consent given or authorised by the holder of parental responsibility over the child, please contact us by using any of the contact information provided within Section 14 of this document.

Children under the age of 16 may use the App [or Website] only if Mylan is provided with the contact details (i.e., email address) of their parent(s) or any holder of parental responsibility over them, and Mylan has received consent from the parent(s) or holder of parental responsibility regarding the processing of the personal data relating to their children who wish to use the App [or Website].


The privacy policy may be modified by Mylan at any time.

Should Mylan wish to adjust the privacy policy (e.g. should Mylan intend to use your personal data for purposes other than what is stipulated in the identifiable privacy policy in force at the time of data collection), notice of any such modifications will be posted in a revised version of the current privacy policy and the revised version will be effective when it is posted.

Mylan will notify you of such changes by posting them on the privacy policy’s page or by sending you an email or other notification.


For any questions or comments relating to the privacy policy, the way Mylan collects and uses your personal data, or for exercising your rights related to your collected personal data (See section 6), please contact the relevant Mylan service via:

Mylan has also appointed a Data Protection Officer.

Contact Details of DPO: dataprivacy@mylan.com

You are Leaving Mylan

You are arriving at a third-party site that contains content that is not controlled by Mylan.

By clicking "Continue", you acknowledge and agree to the terms and/or the other statements set forth below.


In connection with the proposed acquisition of Meda AB (publ.) (“Meda”) by Mylan N.V. (“Mylan”) (the “Meda Acquisition”) and the related offer by Mylan for the shares of Meda (the “Offer”), you acknowledge the following:

Forward-Looking Statements
The communications on this website contain “forward-looking statements.” Such forward-looking statements may include, without limitation, statements about the Meda Acquisition, benefits and synergies of the Meda Acquisition, future opportunities for Mylan, Meda, or the combined company and products and any other statements regarding Mylan’s, Meda’s or the combined company’s future operations, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, competition and other expectations and targets for future periods. These may often be identified by the use of words such as “will”, “may”, “could”, “should”, “would”, “project”, “believe”, “anticipate”, “expect”, “plan”, “estimate”, “forecast”, “potential”, “intend”, “continue”, “target” and variations of these words or comparable words. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: uncertainties related to the Meda Acquisition, including as to the timing of the Meda Acquisition; uncertainties as to whether Mylan will be able to complete the Meda Acquisition; the possibility that competing offers will be made; the possibility that certain conditions to the completion of the Offer will not be satisfied; the possibility that Mylan will be unable to obtain regulatory approvals for the Meda Acquisition or be required, as a condition to obtaining regulatory approvals, to accept conditions that could reduce the anticipated benefits of the Meda Acquisition; the ability to meet expectations regarding the accounting and tax treatments of the Meda Acquisition, changes in relevant tax and other laws, including but not limited to changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; the integration of Meda being more difficult, time-consuming or costly than expected; operating costs, customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with employees, customers, clients or suppliers) being greater than expected following the Meda Acquisition; the retention of certain key employees of Meda being difficult; the possibility that Mylan may be unable to achieve expected synergies and operating efficiencies in connection with the Meda Acquisition within the expected time-frames or at all and to successfully integrate Meda; expected or targeted future financial and operating performance and results; the capacity to bring new products to market, including but not limited to where Mylan uses its business judgment and decides to manufacture, market and/or sell products, directly or through third parties, notwithstanding the fact that allegations of patent infringement(s) have not been finally resolved by the courts (i.e., an “at-risk launch”); any regulatory, legal, or other impediments to Mylan’s ability to bring new products to market; success of clinical trials and Mylan’s ability to execute on new product opportunities; any changes in or difficulties with our inventory of, and our ability to manufacture and distribute, the EpiPen® Auto-Injector to meet anticipated demand; the scope, timing and outcome of any ongoing legal proceedings and the impact of any such proceedings on financial condition, results of operations and/or cash flows; the ability to protect intellectual property and preserve intellectual property rights; the effect of any changes in customer and supplier relationships and customer purchasing patterns; the ability to attract and retain key personnel; changes in third-party relationships; the impact of competition; changes in the economic and financial conditions of the businesses of Mylan, Meda or the combined company; the inherent challenges, risks and costs in identifying, acquiring and integrating complementary or strategic acquisitions of other companies, products or assets and in achieving anticipated synergies; uncertainties and matters beyond the control of management; and inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements, and the providing of estimates of financial measures, in accordance with accounting principles generally accepted in the U.S. and related standards or on an adjusted basis. For more detailed information on the risks and uncertainties associated with Mylan’s business activities, see the risks described in Mylan’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2015 and June 30, 2015 and its other filings with the Securities and Exchange Commission (the “SEC”). These risks and uncertainties also include those risks and uncertainties that will be discussed in the offer document to be filed with the Swedish Financial Supervisory Authority (the “SFSA”) (Sw. Finansinspektionen), the Registration Statement on Form S-4 to be filed with the SEC and the EU Prospectus to be filed with the Netherlands Authority for the Financial Markets (the “AFM”) or another competent EU authority. You can access Mylan’s filings with the SEC through the SEC website at www.sec.gov, and Mylan strongly encourages you to do so. Mylan undertakes no obligation to update any statements herein for revisions or changes after the date of such statement, except as required by law.

Additional Information
In connection with the Offer, an offer document will be filed with the SFSA and published by Mylan upon approval by the SFSA. In addition, Mylan expects to file certain materials with the SEC, including, among other materials, a Registration Statement on Form S-4. Mylan also expects to file an EU Prospectus with the AFM or another competent EU authority. The communications on this website are not intended to be, and are not, a substitute for such documents or for any other document that Mylan may file with the SFSA, the SEC, the AFM or any other competent EU authority in connection with the Offer. The communications on this website contain advertising materials (reclame-uitingen) in connection with the Offer as referred to in Section 5:20 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). INVESTORS AND SECURITYHOLDERS OF MEDA ARE URGED TO READ ANY DOCUMENTS FILED WITH THE SFSA, THE SEC AND THE AFM OR ANY OTHER COMPETENT EU AUTHORITY CAREFULLY AND IN THEIR ENTIRETY (IF AND WHEN THEY BECOME AVAILABLE) BEFORE MAKING AN INVESTMENT DECISION BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT MYLAN, MEDA AND THE OFFER. Such documents will be available free of charge through the website maintained by the SEC at www.sec.gov, on this website or, to the extent filed with the AFM, through the website maintained by the AFM at www.afm.nl, or by directing a request to Mylan at 724.514.1813 or investor.relations@mylan.com. Any materials filed by Mylan with the SFSA, the SEC, the AFM or any other competent EU authority that are required to be mailed to Meda shareholders will also be mailed to such shareholders.

Further Information
The Offer is not being made to persons whose participation in the Offer requires that an additional offer document be prepared or registration effected or that any other measures be taken in addition to those required under Swedish law (including the Swedish Takeover Rules), Dutch law and U.S. law. The distribution of the communications on this website in certain jurisdictions may be restricted or affected by the laws of such jurisdictions. Accordingly, copies of the communications on this website are not being, and must not be, mailed or otherwise forwarded, distributed or sent in, into or from any such jurisdiction. Therefore, persons who receive the communications on this website (including, without limitation, nominees, trustees and custodians) and are subject to the laws of any such jurisdiction will need to inform themselves about, and observe, any applicable restrictions or requirements. Any failure to do so may constitute a violation of the securities laws of any such jurisdiction. To the fullest extent permitted by applicable law, Mylan disclaims any responsibility or liability for the violations of any such restrictions by any person. The Offer is not being made, and communications related to the Offer on this website may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in, any jurisdiction in which the making of the Offer, the distribution of such communications or the acceptance of any tender of shares would contravene applicable laws or regulations or require further offer documents, filings or other measures in addition to those required under Swedish law (including the Swedish Takeover Rules), Dutch law and U.S. law.


I samband med det föreslagna förvärvet av Meda AB (publ.) (”Meda”) att genomföras av Mylan N.V. (”Mylan”) (”Förvärvet av Meda”) och det i samband därmed av Mylan lämnade uppköpserbjudandet avseende aktierna i Meda (”Erbjudandet”), bekräftar du härmed följande:

Framåtriktad information
Informationen på denna webbplats innehåller ”framåtriktad information”. Sådan framåtriktad information kan innehålla, men är inte begränsad till, information om Förvärvet av Meda, fördelar och synergier med Förvärvet av Meda, framtida möjligheter för Mylan, Meda eller det sammanslagna bolaget samt produkter och annan information avseende Mylans, Medas eller det sammanslagna bolagets framtida verksamhet, förväntade affärsnivåer, förväntade lönsamhet, planerade åtgärder, förväntade tillväxt, marknadsmöjligheter, strategier, konkurrens och andra förväntningar och målsättningar för framtida perioder. Sådan information kan ofta kännas igen då den innehåller uttryck som ”kommer”, ”kan”, ”skulle”, ”bör”, ”ska”, ”bedömer”, ”tror”, ”förutser”, ”förväntar”, ”planerar”, ”uppskattar”, ”prognostiserar”, ”potentiell”, ”avser”, ”fortsätter”, ”mål” samt liknande uttryck eller jämförbara ord. Eftersom framåtblickande uttalanden i sig innebär risker och osäkerheter kan de faktiska framtida resultaten avvika väsentligt från dem som uttrycks eller antyds i sådana framtidsinriktade uttalanden. Faktorer som kan orsaka eller bidra till sådana avvikelser är, men är inte begränsade till: osäkerheter relaterade till Förvärvet av Meda, inklusive timingen av Förvärvet av Meda; osäkerheter avseende om Mylan kommer kunna fullfölja Förvärvet av Meda; möjligheten att någon lämnar ett konkurrerande erbjudande; möjligheten att vissa av villkoren för fullföljande av Erbjudandet inte uppfylls; möjligheten att Mylan inte kommer att erhålla erforderliga myndighetsgodkännanden för Förvärvet av Meda eller vara tvungna, för att erhålla myndighetsgodkännanden, att acceptera villkor som kan reducera de förväntade fördelarna med Förvärvet av Meda; förmågan att möta förväntningarna avseende hantering av redovisning och skatt för Förvärvet av Meda, förändringar i skattelagstiftning eller annan lagstiftning, inklusive men inte begränsat till förändringar av vård- och läkemedelslagstiftning och bestämmelser i USA och utomlands; integrationen av Meda blir svårare, mer tidskrävande eller kostsam än förväntat; operativa kostnader, förlust av kunder och störningar i verksamheten (inklusive, men inte begränsat till, svårigheter att bibehålla medarbetare, kunder, klienter eller underleverantörer) blir större än förväntat efter Förvärvet av Meda; svårigheter med att behålla vissa nyckelpersoner i Meda; möjligheten att Mylan inte kan uppnå förväntade synergier och effektiviseringar i verksamheten i samband med Förvärvet av Meda inom den förväntade tidsramen eller att alls lyckas med att integrera Meda; förväntade eller mål för framtida finansiella och operativa prestationer och resultat; förmågan att introducera nya produkter till marknaden, inklusive men inte begränsat till när Mylan gör affärsmässiga bedömningar och beslutar att tillverka, marknadsföra och/eller sälja produkter, direkt eller genom tredje part, trots att invändningar om patentintrång inte slutligen har avgjorts av domstol (d.v.s. en ”at-risk launch”); eventuella regulatoriska, legala eller andra hinder för Mylans möjlighet att introducera nya produkter på marknaden; framgång i kliniska studier och Mylans förmåga att agera på nya produktmöjligheter; eventuella förändringar i eller svårigheter med vår lagerhållning av, och vår förmåga att tillverka och distribuera, autoinjektorn EpiPen för att möta en förväntad efterfrågan; omfattningen, timingen och slutresultatet av eventuella pågående rättsliga förfaranden och sådana förfarandens påverkan på finansiell ställning, resultat av verksamheten och/eller kassaflöde; förmågan att skydda immateriella rättigheter och försvara dessa rättigheter; effekten av eventuella förändringar vad gäller förhållandet till kunder och underleverantörer och kunders köpmönster; förmågan att attrahera och bibehålla nyckelpersoner; ändringar i relationen till tredje part; påverkan av konkurrens; förändringar i ekonomiska och finansiella förutsättningar för verksamheten i Mylan, Meda eller det sammanslagna bolaget; de inneboende utmaningarna, kostnaderna och riskerna med att identifiera, förvärva och integrera komplementerande eller strategiska förvärv av andra företag, produkter eller tillgångar och i att uppnå de förväntade synergierna; osäkerheter och händelser utanför ledningens kontroll; och inneboende osäkerheter med estimat och bedömningar använda vid framställningen av finansiella rapporter, och tillhandahållandet av estimat och finansiella mått, i enlighet med allmänt accepterade redovisningsprinciper i USA och tillhörande standarder eller på en justerad grund. För mer detaljerad information om riskerna och osäkerheterna förenade med Mylans verksamhet, se riskerna beskrivna i Mylans kvartalsrapport på Form 10-Q för kvartalsperioderna som avslutades 31 mars 2015 och 30 juni 2015, samt andra inlämnade dokument hos Securities and Exchange Commission (”SEC”). Dessa risker och osäkerheter inkluderar även de risker och osäkerheter som kommer att diskuteras i erbjudandehandlingen som ska lämnas in till Finansinspektionen, Registration Statement på Form S-4 som ska lämnas in till SEC och EU-prospektet som ska lämnas in till nederländska Authority for the Financial Markets (”AFM”) eller annan behörig myndighet inom EU. Åtkomst till Mylans inlämnade dokument hos SEC är möjlig via SEC:s webbplats www.sec.gov, och Mylan rekommenderar starkt alla att läsa dessa. Förutom vad som krävs enligt tillämplig lag, åtar sig inte Mylan någon skyldighet att uppdatera uttalanden häri för revideringar eller ändringar efter dagen för sådant uttalande.

I samband med Erbjudandet kommer en erbjudandehandling att lämnas in till Finansinspektionen och när Finansinspektionen godkänt erbjudandehandlingen kommer den även publiceras på Mylans webbplats. Därutöver förväntas Mylan att lämna in vissa handlingar till SEC, inklusive bland annat ett Registration Statement på Form S-4. Mylan förväntas även lämna in ett EU-prospekt till AFM eller annan behörig myndighet inom EU. Informationen på denna webbplats är inte avsedd att vara och utgör inte ett substitut för sådana dokument eller för eventuella andra dokument som Mylan kan komma att lämna in till Finansinspektionen, SEC, AFM eller någon annan behörig myndighet inom EU i samband med Erbjudandet. Informationen på denna webbplats innehåller marknadsföringsmaterial (reclame-uitingen) hänförligt till Erbjudandet så som framgår av paragraf 5:20 i nederländska Financial Supervision Act (Wet op het financieel toezicht). INVESTERARE OCH VÄRDEPAPPERSINNEHAVARE I MEDA UPPMANAS ATT NOGGRANNT OCH I HELHET LÄSA ALLA DOKUMENT INLÄMNADE TILL FINANSINSPEKTIONEN, SEC OCH AFM ELLER NÅGON ANNAN BEHÖRIG MYNDIGHET INOM EU (OM OCH NÄR DE BLIR TILLGÄNGLIGA) INNAN ETT INVESTERINGSBESLUT FATTAS EFTERSOM DE KOMMER INNEHÅLLA VIKTIG INFORMATION OM MYLAN, MEDA OCH ERBJUDANDET. Sådana dokument kommer vara fritt tillgängliga via den webbplats som tillhandahålls av SEC www.sec.gov, på denna webbplats eller, för vad som lämnas in till AFM, via den webbplats som tillhandahålls av AFM www.afm.nl, eller genom en direkt förfrågan till Mylan på + 1 724 514 1813 eller investor.relations@mylan.com. Eventuellt material inlämnat av Mylan till Finansinspektionen, SEC, AFM eller någon annan behörig myndighet inom EU och som behöver skickas till aktieägare i Meda kommer också att skickas till sådana aktieägare.

Ytterligare information
Erbjudandet lämnas inte till personer vars deltagande i Erbjudandet kräver att ytterligare erbjudandehandlingar upprättas eller registrering sker eller att någon annan åtgärd vidtas utöver vad som krävs enligt svensk lag (inklusive takeover-reglerna), nederländsk lag och amerikansk lag. Distribution av informationen på denna webbplats kan i vissa jurisdiktioner vara föremål för restriktioner eller påverkas av lagar i sådana jurisdiktioner. Exemplar av informationen på denna webbplats skickas således inte, och får inte skickas, eller på annat sätt vidarebefordras, distribueras eller sändas, inom, in i eller från någon sådan jurisdiktion. Därför måste personer som mottar informationen på denna webbplats (inklusive, men inte begränsat till, förvaltare, förmyndare och panthavare) och som är underkastade lagarna i en sådan jurisdiktion, informera sig om, och iaktta, eventuella tillämpliga lagar och regler. Underlåtenhet att göra detta kan utgöra en överträdelse av värdepapperslagar i en sådan jurisdiktion. Mylan avsäger sig, i den mån det är möjligt enligt tillämplig lag, allt ansvar för personers eventuella överträdelser av sådana bestämmelser. Erbjudandet lämnas inte, och information på denna webbplats hänförlig till Erbjudandet får inte distribueras, vare sig direkt eller indirekt, i eller till, och inga anmälningssedlar kommer att accepteras från eller på uppdrag av aktieägare i något land där Erbjudandet, distribution av sådan information eller godkännande av accept av Erbjudandet skulle strida mot tillämpliga lagar eller regler eller skulle kräva att ytterligare erbjudandehandlingar upprättas eller registrering sker eller att någon annan åtgärd vidtas utöver vad som krävs enligt svensk lag (inklusive takeover-reglerna), nederländsk lag och amerikansk lag.